207 related articles for article (PubMed ID: 28178415)
1. Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.
Sharma S; Kotamraju VR; Mölder T; Tobi A; Teesalu T; Ruoslahti E
Nano Lett; 2017 Mar; 17(3):1356-1364. PubMed ID: 28178415
[TBL] [Abstract][Full Text] [Related]
2. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
[TBL] [Abstract][Full Text] [Related]
3. Peptide-guided nanoparticles for glioblastoma targeting.
Säälik P; Lingasamy P; Toome K; Mastandrea I; Rousso-Noori L; Tobi A; Simón-Gracia L; Hunt H; Paiste P; Kotamraju VR; Bergers G; Asser T; Rätsep T; Ruoslahti E; Bjerkvig R; Friedmann-Morvinski D; Teesalu T
J Control Release; 2019 Aug; 308():109-118. PubMed ID: 31255690
[TBL] [Abstract][Full Text] [Related]
4. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.
Agemy L; Kotamraju VR; Friedmann-Morvinski D; Sharma S; Sugahara KN; Ruoslahti E
Mol Ther; 2013 Dec; 21(12):2195-204. PubMed ID: 23959073
[TBL] [Abstract][Full Text] [Related]
5. Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.
Sharma S; Mann AP; Mölder T; Kotamraju VR; Mattrey R; Teesalu T; Ruoslahti E
J Control Release; 2017 Dec; 268():49-56. PubMed ID: 29030222
[TBL] [Abstract][Full Text] [Related]
6. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
7. Homing Peptides for Cancer Therapy.
Lingasamy P; Teesalu T
Adv Exp Med Biol; 2021; 1295():29-48. PubMed ID: 33543454
[TBL] [Abstract][Full Text] [Related]
8. New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.
Paasonen L; Sharma S; Braun GB; Kotamraju VR; Chung TD; She ZG; Sugahara KN; Yliperttula M; Wu B; Pellecchia M; Ruoslahti E; Teesalu T
Chembiochem; 2016 Apr; 17(7):570-5. PubMed ID: 26895508
[TBL] [Abstract][Full Text] [Related]
9. Improved breast cancer cell-specific intracellular drug delivery and therapeutic efficacy by coupling decoration with cell penetrating peptide and SP90 peptide.
Fan LQ; Du GX; Li PF; Li MW; Sun Y; Zhao LM
Biomed Pharmacother; 2016 Dec; 84():1783-1791. PubMed ID: 27899251
[TBL] [Abstract][Full Text] [Related]
10. Transtumoral targeting enabled by a novel neuropilin-binding peptide.
Roth L; Agemy L; Kotamraju VR; Braun G; Teesalu T; Sugahara KN; Hamzah J; Ruoslahti E
Oncogene; 2012 Aug; 31(33):3754-63. PubMed ID: 22179825
[TBL] [Abstract][Full Text] [Related]
11. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
Gao H; Yang Z; Zhang S; Cao S; Pang Z; Yang X; Jiang X
J Control Release; 2013 Dec; 172(3):921-8. PubMed ID: 24120853
[TBL] [Abstract][Full Text] [Related]
12. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y
Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906
[TBL] [Abstract][Full Text] [Related]
13. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
14. De novo design of a tumor-penetrating peptide.
Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
[TBL] [Abstract][Full Text] [Related]
15. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
16. Tumor-penetrating peptide for systemic targeting of Tenascin-C.
Lingasamy P; Tobi A; Kurm K; Kopanchuk S; Sudakov A; Salumäe M; Rätsep T; Asser T; Bjerkvig R; Teesalu T
Sci Rep; 2020 Apr; 10(1):5809. PubMed ID: 32242067
[TBL] [Abstract][Full Text] [Related]
17. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
Gao H; Zhang Q; Yang Y; Jiang X; He Q
Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
19. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy.
Cong Z; Zhang L; Ma SQ; Lam KS; Yang FF; Liao YH
ACS Nano; 2020 Feb; 14(2):1958-1970. PubMed ID: 32023048
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.
Priwitaningrum DL; Jentsch J; Bansal R; Rahimian S; Storm G; Hennink WE; Prakash J
Int J Pharm; 2020 Jul; 585():119535. PubMed ID: 32534162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
